TY - JOUR
T1 - Circulating vitamin D and breast cancer risk
T2 - an international pooling project of 17 cohorts
AU - Visvanathan, Kala
AU - Mondul, Alison M.
AU - Zeleniuch-Jacquotte, Anne
AU - Wang, Molin
AU - Gail, Mitchell H.
AU - Yaun, Shiaw Shyuan
AU - Weinstein, Stephanie J.
AU - McCullough, Marjorie L.
AU - Eliassen, A. Heather
AU - Cook, Nancy R.
AU - Agnoli, Claudia
AU - Almquist, Martin
AU - Black, Amanda
AU - Buring, Julie E.
AU - Chen, Chu
AU - Chen, Yu
AU - Clendenen, Tess
AU - Dossus, Laure
AU - Fedirko, Veronika
AU - Gierach, Gretchen L.
AU - Giovannucci, Edward L.
AU - Goodman, Gary E.
AU - Goodman, Marc T.
AU - Guénel, Pascal
AU - Hallmans, Göran
AU - Hankinson, Susan E.
AU - Horst, Ronald L.
AU - Hou, Tao
AU - Huang, Wen Yi
AU - Jones, Michael E.
AU - Joshu, Corrine E.
AU - Kaaks, Rudolf
AU - Krogh, Vittorio
AU - Kühn, Tilman
AU - Kvaskoff, Marina
AU - Lee, I. Min
AU - Mahamat-Saleh, Yahya
AU - Malm, Johan
AU - Manjer, Jonas
AU - Maskarinec, Gertraud
AU - Millen, Amy E.
AU - Mukhtar, Toqir K.
AU - Neuhouser, Marian L.
AU - Robsahm, Trude E.
AU - Schoemaker, Minouk J.
AU - Sieri, Sabina
AU - Sund, Malin
AU - Swerdlow, Anthony J.
AU - Thomson, Cynthia A.
AU - Ursin, Giske
AU - Wactawski-Wende, Jean
AU - Wang, Ying
AU - Wilkens, Lynne R.
AU - Wu, Yujie
AU - Zoltick, Emilie
AU - Willett, Walter C.
AU - Smith-Warner, Stephanie A.
AU - Ziegler, Regina G.
N1 - Publisher Copyright:
© 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2023/1
Y1 - 2023/1
N2 - Laboratory and animal research support a protective role for vitamin D in breast carcinogenesis, but epidemiologic studies have been inconclusive. To examine comprehensively the relationship of circulating 25-hydroxyvitamin D [25(OH)D] to subsequent breast cancer incidence, we harmonized and pooled participant-level data from 10 U.S. and 7 European prospective cohorts. Included were 10,484 invasive breast cancer cases and 12,953 matched controls. Median age (interdecile range) was 57 (42–68) years at blood collection and 63 (49–75) years at breast cancer diagnosis. Prediagnostic circulating 25(OH)D was either newly measured using a widely accepted immunoassay and laboratory or, if previously measured by the cohort, calibrated to this assay to permit using a common metric. Study-specific relative risks (RRs) for season-standardized 25(OH)D concentrations were estimated by conditional logistic regression and combined by random-effects models. Circulating 25(OH)D increased from a median of 22.6 nmol/L in consortium-wide decile 1 to 93.2 nmol/L in decile 10. Breast cancer risk in each decile was not statistically significantly different from risk in decile 5 in models adjusted for breast cancer risk factors, and no trend was apparent (P-trend = 0.64). Compared to women with sufficient 25(OH)D based on Institute of Medicine guidelines (50– < 62.5 nmol/L), RRs were not statistically significantly different at either low concentrations (< 20 nmol/L, 3% of controls) or high concentrations (100– < 125 nmol/L, 3% of controls; ≥ 125 nmol/L, 0.7% of controls). RR per 25 nmol/L increase in 25(OH)D was 0.99 [95% confidence intervaI (CI) 0.95–1.03]. Associations remained null across subgroups, including those defined by body mass index, physical activity, latitude, and season of blood collection. Although none of the associations by tumor characteristics reached statistical significance, suggestive inverse associations were seen for distant and triple negative tumors. Circulating 25(OH)D, comparably measured in 17 international cohorts and season-standardized, was not related to subsequent incidence of invasive breast cancer over a broad range in vitamin D status.
AB - Laboratory and animal research support a protective role for vitamin D in breast carcinogenesis, but epidemiologic studies have been inconclusive. To examine comprehensively the relationship of circulating 25-hydroxyvitamin D [25(OH)D] to subsequent breast cancer incidence, we harmonized and pooled participant-level data from 10 U.S. and 7 European prospective cohorts. Included were 10,484 invasive breast cancer cases and 12,953 matched controls. Median age (interdecile range) was 57 (42–68) years at blood collection and 63 (49–75) years at breast cancer diagnosis. Prediagnostic circulating 25(OH)D was either newly measured using a widely accepted immunoassay and laboratory or, if previously measured by the cohort, calibrated to this assay to permit using a common metric. Study-specific relative risks (RRs) for season-standardized 25(OH)D concentrations were estimated by conditional logistic regression and combined by random-effects models. Circulating 25(OH)D increased from a median of 22.6 nmol/L in consortium-wide decile 1 to 93.2 nmol/L in decile 10. Breast cancer risk in each decile was not statistically significantly different from risk in decile 5 in models adjusted for breast cancer risk factors, and no trend was apparent (P-trend = 0.64). Compared to women with sufficient 25(OH)D based on Institute of Medicine guidelines (50– < 62.5 nmol/L), RRs were not statistically significantly different at either low concentrations (< 20 nmol/L, 3% of controls) or high concentrations (100– < 125 nmol/L, 3% of controls; ≥ 125 nmol/L, 0.7% of controls). RR per 25 nmol/L increase in 25(OH)D was 0.99 [95% confidence intervaI (CI) 0.95–1.03]. Associations remained null across subgroups, including those defined by body mass index, physical activity, latitude, and season of blood collection. Although none of the associations by tumor characteristics reached statistical significance, suggestive inverse associations were seen for distant and triple negative tumors. Circulating 25(OH)D, comparably measured in 17 international cohorts and season-standardized, was not related to subsequent incidence of invasive breast cancer over a broad range in vitamin D status.
KW - 25-Hydroxyvitamin D
KW - Biomarker
KW - Breast cancer
KW - Calibration
KW - Pooled analysis
KW - Prospective cohort study
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=85145419390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145419390&partnerID=8YFLogxK
U2 - 10.1007/s10654-022-00921-1
DO - 10.1007/s10654-022-00921-1
M3 - Article
C2 - 36593337
AN - SCOPUS:85145419390
SN - 0393-2990
VL - 38
SP - 11
EP - 29
JO - European Journal of Epidemiology
JF - European Journal of Epidemiology
IS - 1
ER -